6JH Stock Overview A clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of solid and liquid tumors. More details
Risk Analysis + 1 more risk
See All Risk Checks Capture your thoughts, links and company narrative
Price History & Performance
Summary of share price highs, lows and changes for IN8bio Historical stock prices Current Share Price US$0.24 52 Week High US$1.52 52 Week Low US$0.20 Beta 0.0029 1 Month Change -15.38% 3 Month Change -6.92% 1 Year Change -80.79% 3 Year Change -93.70% 5 Year Change n/a Change since IPO -93.89%
Recent News & Updates
IN8bio Reports Continued Progression-Free Survival in Phase 1 Investigator-Sponsored Trial of INB-100 Allogeneic Gamma-Delta T Cells for Leukemias at the 2024 American Society of Hematology Annual Meeting Dec 10
IN8bio Reports Continued Durable Remissions in Phase 1 Trial of INB-200 in Plenary Oral Presentation at the Society for Neuro-Oncology (SNO) Annual Meeting Nov 27 IN8bio, Inc. announced that it expects to receive $12.405547 million in funding Oct 02
IN8bio, Inc. Announces Clinical Pipeline Prioritization to Focus on INB-100 for Acute Myeloid Leukemia Sep 05
IN8bio, Inc. Announces Updated Positive Clinical Data from Both of the Phase 1 Investigator-Sponsored Trials of INB-100 for Hematological Malignancies and INB-200 for GBM Aug 13
IN8bio, Inc. Presents Positive Data Demonstrating Durable 1-Year Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100 Jun 15 See more updates
IN8bio Reports Continued Progression-Free Survival in Phase 1 Investigator-Sponsored Trial of INB-100 Allogeneic Gamma-Delta T Cells for Leukemias at the 2024 American Society of Hematology Annual Meeting Dec 10
IN8bio Reports Continued Durable Remissions in Phase 1 Trial of INB-200 in Plenary Oral Presentation at the Society for Neuro-Oncology (SNO) Annual Meeting Nov 27 IN8bio, Inc. announced that it expects to receive $12.405547 million in funding Oct 02
IN8bio, Inc. Announces Clinical Pipeline Prioritization to Focus on INB-100 for Acute Myeloid Leukemia Sep 05
IN8bio, Inc. Announces Updated Positive Clinical Data from Both of the Phase 1 Investigator-Sponsored Trials of INB-100 for Hematological Malignancies and INB-200 for GBM Aug 13
IN8bio, Inc. Presents Positive Data Demonstrating Durable 1-Year Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100 Jun 15
IN8bio, Inc. Presents Progression-Free Survival Update from Phase 1 Study of INB-200 At 2024 American Society of Clinical Oncology Annual Meeting Jun 05
In8bio Demonstrates Robust and Reproducible Gamma-Delta T Cell Therapy Manufacturing in Oral Presentation At Asgct 2024 May 15
In8bio, Inc. Doses First Patient in Phase 2 Clinical Trial of Inb-400 in Newly Diagnosed Glioblastoma Apr 30
IN8bio, Inc., Annual General Meeting, Jun 12, 2024 Apr 28
IN8bio, Inc. Announces New Preclinical Data for Gamma-Delta nsCAR-T Cell Therapy Platform at AACR 2024 Apr 10
New major risk - Financial position Mar 15
IN8bio, Inc. to Present New Preclinical Data on Novel Gamma-Delta CAR Platform Candidate at AACR Annual Meeting 2024 Mar 06
IN8bio Announces Publication on Novel Gamma-Delta T Cell Therapy for Glioblastoma in Frontiers in Immunology Feb 15 IN8bio, Inc. announced that it has received $14.442298 million in funding from Bios Equity Partners LP Dec 29
New major risk - Shareholder dilution Dec 18 IN8bio, Inc. Announces Positive Clinical Update Demonstrating Continued Durable Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100 in Leukemia
IN8bio, Inc. Appoints Corinne Epperly to the Board of Directors Dec 07
IN8bio, Inc.’s INB-200 Demonstrates Extended Progression-Free Survival in Patients with Newly Diagnosed Glioblastoma Nov 21
IN8bio, Inc. Presents Biologic Correlative Data from the Inb-200 Phase 1 Trial in Newly Diagnosed Glioblastoma At the Society for Immunotherapy of Cancer's 38Th Annual Meeting Nov 07 IN8bio, Inc. Presents Positive Data Update from Induced Pluripotent Stem Cell (iPSC) Platform at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
IN8bio Completes Dose Escalation in Phase 1 Trial of INB-100, a Potential First-in-Class Gamma-Delta T Cell Therapy for the Treatment of Leukemias, and Initiates Enrollment for the Phase 2 Trial of INB-400 in Newly Diagnosed Glioblastoma Oct 13
IN8bio, Inc. Announces Presentations at the Society for Immunology of Cancer 38th Annual Meeting Oct 01
IN8bio, Inc. Announces Updated Data from the Ongoing Phase 1 Clinical Trial of Inb-200 in Patients with Newly Diagnosed Glioblastoma Multiforme Jun 06
IN8bio, Inc. Announces Positive Preclinical Data Underscoring the Potential of Its DeltEx Gamma-Delta T Cells to Target and Kill Ovarian Cancer May 18
IN8bio Provides INB-200 Clinical Update and Outlines 2023 Pipeline Goals Jan 06
High number of new and inexperienced directors Dec 16
In8bio Announces New Data At Ash Showing 100% of Cohort 1 Patients Maintained Durable Complete Response in Ongoing Phase 1 Trial of Inb-100 Dec 13
IN8bio Announces FDA Clearance to Initiate A Phase 2 Clinical Trial of INB-400 Gamma-Delta T Cells for Glioblastoma Dec 09
High number of new and inexperienced directors Nov 17
IN8bio to Present Positive Early Data from Ongoing Phase 1 Study of INB-100 at the 64th American Society of Hematology Annual Meeting Nov 04
High number of new and inexperienced directors Nov 01
High number of new and inexperienced directors Oct 02
IN8bio, Inc. Appoints Michael R. Bishop to Its Scientific Advisory Board Sep 09
Independent Director recently bought €197k worth of stock Aug 19
IN8bio, Inc. Provides Clinical Update from Ongoing Phase 1 Trial of INB-100 Jul 28
IN8bio, Inc. Appoints Kenneth R. Lamontagne as Senior Vice President, Business Development Jul 13
IN8bio, Inc. Announces Positive Glioblastoma Multiforme (Gbm) Clinical Updates from the INB-200 Phase 1 Trial Presented At Asco 2022 Jun 07
IN8bio Announces Data Emerging from its Recently Unveiled Gamma-Delta T cell “Off-the-Shelf” Induced Pluripotent Stem Cell Platform May 18
IN8bio, Inc., Annual General Meeting, Jun 01, 2022 Apr 23
IN8bio, Inc. Presents Clinical Update from the Ongoing Phase 1 Trial of INB-100 Mar 29 Shareholder Returns 6JH DE Biotechs DE Market 7D -5.5% 1.1% -0.2% 1Y -80.8% -14.5% 7.0%
See full shareholder returns
Return vs Market: 6JH underperformed the German Market which returned 7% over the past year.
Price Volatility Is 6JH's price volatile compared to industry and market? 6JH volatility 6JH Average Weekly Movement 34.9% Biotechs Industry Average Movement 7.0% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.7% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: 6JH's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 6JH's weekly volatility has increased from 21% to 35% over the past year.
About the Company Founded Employees CEO Website 2016 18 William Ho in8bio.com
IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of solid and liquid tumors. Its lead product candidates include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of GBM and other cancers; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with hematologic malignancies undergoing hematopoietic stem cell transplantation. The company develops INB-300 and INB-500 that are in preclinical phase for treatment of acute myeloid leukemia, and other solid and hematological tumor types.
Show more IN8bio, Inc. Fundamentals Summary How do IN8bio's earnings and revenue compare to its market cap? 6JH fundamental statistics Market cap €16.34m Earnings (TTM ) -€30.63m Revenue (TTM ) n/a
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 6JH income statement (TTM ) Revenue US$0 Cost of Revenue US$0 Gross Profit US$0 Other Expenses US$31.88m Earnings -US$31.87m
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/26 04:24 End of Day Share Price 2024/12/23 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources IN8bio, Inc. is covered by 7 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Kalpit Patel B. Riley Securities, Inc. Swayampakula Ramakanth H.C. Wainwright & Co. Soumit Roy JonesTrading Institutional Services, LLC
Show 4 more analysts 